NEW YORK, May 26, 2011 /PRNewswire/ — Signal Genetics, the
parent company of Myeloma Health LLC and Respira Health LLC, a
privately held predictive genetic testing company focused on
oncology, announced today a new agreement under which NeoGenomics
Laboratories will offer Signal Genetics’ new gene expression
profile test for Multiple Myeloma (MyPRS™) to pathologists
and hospital-based hematologists/oncologists nationwide.
Myeloma Prognostic Risk Signature™ (MyPRS) offers
the most detailed expression profiling information for multiple
myeloma patients available on the market. MyPRS analyzes and
applies a proprietary algorithm to a defined number of relevant
genes to determine the gene expression profile associated with the
patient’s condition. The gene expression profiling behind MyPRS
allows physicians to gain a predictive view of their patient’s
prognosis, enabling truly personalized treatment options. The
technology has been published in more than 70 peer-reviewed
scientific journals and is powered by the world’s largest outcomes
database for multiple myeloma patients.
Douglas VanOort, Chairman and CEO of NeoGenomics, stated, “Our
new partnership with Signal Genetics provides broad access to this
important new prognostic marker for patients with Multiple Myeloma
and complements our strategy of bringing novel products to our
customers. The agreement also provides NeoGenomics a right of
first negotiation to market any genomic and transcriptomic-based
diagnostic tests developed and/or introduced by Signal in the
future to pathologists and hospital-based
oncologists/hematologists.”
Under the terms of the agreement, the MyPRS test will be
performed at Signal Genetics’ CLIA-certified laboratory based in
Little Rock, Arkansas and the test results will be incorporated
into NeoGenomics’ test reports and provided to their customer
‘/>”/>
SOURCE
